The impact of the 21-gene Recurrence Score® assay upon physician treatment recommendations in the neoadjuvant setting in lymph node-negative breast cancer patients in a multicenter prospective study in Quebec

被引：0
|
作者：
Yordanova, Mariya
Sideris, Lucas
Dube, Pierre
Boileau, Jean-Francois
Lemieux, Julie
Mihalcioiu, Catalin
Levesque, Sylvie
Guertin, Marie-Claude
Patocskai, Erica
Younan, Rami
Robidoux, Andre
Hassan, Saima
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 05期
关键词：
D O I：
10.1158/1538-7445.SABCS22-P6-01-39
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P6-01-39
引用
收藏
页数：3
相关论文
共 50 条
  • [31] The utility of the 21-gene Oncotype DX Breast Recurrence Score® assay in node-negative breast cancer patients - the final analysis of the Polish real-life survey PONDx
    Jarzab, Michal
    Litwiniuk, Maria
    Innis, Paige
    Lacko, Aleksandra
    Enderle, Gesine
    Czartoryska-Arlukowicz, Bogumila
    Talerczyk, Malgorzata
    Streb, Joanna
    Wysocki, Piotr
    Suchodolska, Grazyna
    Szymanowski, Bartosz
    Duchnowska, Renata
    WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY, 2024, 28 (03): : 245 - 252
  • [32] Prospective multicenter study of the impact of the 21-gene recurrence score (RS) assay on medical oncologist (MO) and patient (pt) adjuvant breast cancer (BC) treatment selection
    Lo, S. S.
    Norton, J.
    Mumby, P. B.
    Smerage, J.
    Kash, J.
    Chew, H. K.
    Hayes, D.
    Epstein, A.
    Albain, K. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [33] Prediction of Risk of Distant Recurrence Using the 21-Gene Recurrence Score in Node-Negative and Node-Positive Postmenopausal Patients With Breast Cancer Treated With Anastrozole or Tamoxifen: A TransATAC Study
    Dowsett, Mitch
    Cuzick, Jack
    Wale, Christopher
    Forbes, John
    Mallon, Elizabeth A.
    Salter, Janine
    Quinn, Emma
    Dunbier, Anita
    Baum, Michael
    Buzdar, Aman
    Howell, Anthony
    Bugarini, Roberto
    Baehner, Frederick L.
    Shak, Steven
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (11) : 1829 - 1834
  • [34] Impact of 21-Gene Expression Assay on Clinical Outcomes in Node-Negative ≤ T1b Breast Cancer
    Pomponio, Maria
    Keele, Luke
    Hilt, Elizabeth
    Burkbauer, Laura
    Goldbach, Macy
    Nazarian, Susanna
    Fox, Kevin
    Tchou, Julia
    ANNALS OF SURGICAL ONCOLOGY, 2020, 27 (05) : 1671 - 1678
  • [35] Impact of 21-Gene Expression Assay on Clinical Outcomes in Node-Negative ≤ T1b Breast Cancer
    Maria Pomponio
    Luke Keele
    Elizabeth Hilt
    Laura Burkbauer
    Macy Goldbach
    Susanna Nazarian
    Kevin Fox
    Julia Tchou
    Annals of Surgical Oncology, 2020, 27 : 1671 - 1678
  • [36] A retrospective study of 21-gene recurrence score assay compared with clinicopathological markers in node-negative, hormone receptor-positive, HER2-negative breast cancer.
    Chen, Junqing
    Wang, Xiaojia
    Chen, Zhanhong
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [37] Association Between 21-Gene Assay Recurrence Score and Locoregional Recurrence Rates in Patients With Node-Positive Breast Cancer
    Woodward, Wendy A.
    Barlow, William E.
    Jagsi, Reshma
    Buchholz, Thomas A.
    Shak, Steven
    Baehner, Frederick
    Whelan, Timothy J.
    Davidson, Nancy E.
    Ingle, James N.
    King, Tari A.
    Ravdin, Peter M.
    Osborne, C. Kent
    Tripathy, Debasish
    Livingston, Robert B.
    Gralow, Julie R.
    Hortobagyi, Gabriel N.
    Hayes, Daniel F.
    Albain, Kathy S.
    JAMA ONCOLOGY, 2020, 6 (04) : 505 - 511
  • [38] Prospective transGEICAM study of the impact of the 21-gene Recurrence Score assay and traditional clinicopathological factors on adjuvant clinical decision making in women with estrogen receptor-positive (ER plus ) node-negative breast cancer
    Albanell, J.
    Gonzalez, A.
    Ruiz-Borrego, M.
    Alba, E.
    Garcia-Saenz, J. A.
    Corominas, J. M.
    Burgues, O.
    Furio, V.
    Rojo, A.
    Palacios, J.
    Bermejo, B.
    Martinez-Garcia, M.
    Limon, M. L.
    Munoz, A. S.
    Martin, M.
    Tusquets, I.
    Rojo, F.
    Colomer, R.
    Faull, I.
    Lluch, A.
    ANNALS OF ONCOLOGY, 2012, 23 (03) : 625 - 631
  • [39] Clinical relevance of the 21-gene Recurrence Score® assay in treatment decisions for patients with node-positive breast cancer in the genomic era
    Mamounas, Eleftherios P.
    Russell, Christy A.
    Lau, Anna
    Turner, Michelle P.
    Albain, Kathy S.
    NPJ BREAST CANCER, 2018, 4
  • [40] Impact of the 21-gene recurrence score assay on treatment decision in early breast cancer (EBC) patients with favourable prognostic factors
    Markopoulos, C.
    BREAST, 2011, 20 : S44 - S44
12345